Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia

Neuroscience

Volumn 98, Issue 1, 2000, Pages 61-67

  Van Kampen, J M ^a   Stoessl, A J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antisense; D1 receptor; Dyskinesias; Levodopa; Rat

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTISENSE OLIGONUCLEOTIDE; APOMORPHINE; BENSERAZIDE; BUTACLAMOL; DOPAMINE 1 RECEPTOR; DOPAMINE 1A RECEPTOR; LEVODOPA; MESSENGER RNA; NOMIFENSINE; OXIDOPAMINE; RACLOPRIDE; RECEPTOR SUBTYPE; RITANSERIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN INJURY; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; DYSKINESIA; GENE EXPRESSION; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SENSITIZATION;

ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; COCAINE; DENERVATION; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DYSKINESIA, DRUG-INDUCED; GENE EXPRESSION; LEVODOPA; MALE; OLIGONUCLEOTIDES, ANTISENSE; OXIDOPAMINE; PHENOTYPE; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; ROTATION; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TRITIUM;

EID: 0034038468     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00090-7     Document Type: Article

References (62)

1. Alexander G.M., Schwartzman R.J., Grothusen J.R., Brainard L., Gordon S.W. Change in brain dopamine receptor in MPTP parkinsonian monkeys following L-Dopa treatment. Brain Res. 625:1993;276-282.
2. Andersson M., Hilbertson A., Cenci M.A. Striatal FosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6:1999;461-474.
3. 2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat. Molec. Brain Res. 11:1991;161-166.
4. 3H-spiperone binding. Brain Res. 379:1986;294-299.
5. 2 agonist in inducing dyskinesia in drug-naïve MPTP monkeys. Adv. Neurol. 60:1993;113-118.
6. Bennett J.P., Landow E.R., Dietrich S., Schuh L.A. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Movement Disord. 9:1994;409-414.
7. 2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1, 2,3,6 tetrahydropyridine-exposed monkeys. J. Pharmac. exp. Ther. 267:1993;275-279.
8. 1 receptor desensitization profile in MPTP-lesioned primates. Eur. J. Pharmacol. 309:1996;13-20.
9. 3H]Spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur. J. Pharmacol. 99:1984;167-175.
10. 2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurobiology. 40:1990;927-933.
11. Brysch W., Schlingensiepen K.H. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents. Cell Molec. Neurobiol. 14:1994;555-567.
12. Cenci M.A., Lee C.S., Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10:1998;2694-2706.
13. Chase T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. 50:(Suppl 5):1998;S17-S25.
14. Chase T.N., Engber T.M., Mouradian M.M. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology. 44:(Suppl 6):1994;S15-S18.
15. 1A dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology. 37:1998;1595-1602.
16. 1-like receptor not coupled to adenylyl cyclase. Neuroscience. 93:1999;1483-1489.
17. 1A-deficient mouse. NeuroReport. 8:1997;2523-2527.
18. 2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of ventrolateral striatum. Neuroscience. 39:1990;59-67.
19. 1-like" dopamine receptor agonists. Pharmacol. Biochem. Behav. 58:1997;551-558.
20. 1-like" receptors that inhibits dopamine-sensitive adenylyl cyclase. Eur. J. Pharmacol. 234:1993;135-136.
21. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., Chen J.S., Iadarola M.J., St.Jean M., Wigle N., Grondin R., Robertson G.S. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of delta FosB-like proteins in both the rodent and primate striatum. Eur. J. Neurosci. 8:1996;365-381.
22. Engber T.M., Susel Z., Kuo S., Gerfen C.R., Chase T.N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal ouput regions of 6-hydroxydopamine lesioned rats. Brain Res. 552:1991;113-118.
23. Engber T.M., Boldry R.C., Kuo S., Chase T.N. Dopaminergic modulation of striatal neuropeptides: differential effects of D(1) and D(2) receptor stimulation on somatostatin, neuropeptide-Y, neurotensin, dynorphin, and enkephalin. Brain Res. 581:1992;261-268.
24. Falardeau P., Bouchard S., Bédard P.J., Boucher R., Di Paolo T. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP-monkeys. Eur. J. Pharmac. 150:1988;59-66.
25. 1 dopamine receptors in various forebrain regions of the rat. Neurosci. Lett. 81:1987;183-187.
26. Gagnon C., Bédard P.J., Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur. J. Pharmac. 178:1990;115-120.
27. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
28. Grondin R., Doan V.D., Gregoire L., Bédard P.J. D-1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology. 52:1999;771-776.
29. Guttman M., Seeman P. L-dopa reverses the elevated density of D2 dopamine receptor in Parkinson's diseased striatum. J. Neural. Transm. 64:1985;93-104.
30. Hebb M.O., Robertson H.A. End-capped antisense oligodeoxynucleotides effectively inhibit gene expression in vivo and offer a low-toxicity alternative to fully modified phosphorothioate oligodeoxynucleotides. Brain Res. Molec. Brain Res. 47:1997;223-228.
31. Henry D.J., White F.J. Repeated cocaine administration causes persistent enhancement of D1 dopamine receptor sensitivity within the rat nucleus accumbens. J. Pharmac. exp. Ther. 258:1991;882-890.
32. Herrero M.T., Augood S.J., Hirsch E.C., Javoy-Agid F., Luquin M.R., Agid Y., Obeso J.A., Emson P.C. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience. 68:1995;1189-1198.
33. 2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. Molec. Brain Res. 42:1996;149-155.
34. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology. 51:(Suppl 2):1998;S2-S9.
35. Juncos J.L., Engber T.M., Raisman R., Susel Z., Thibaut F., Ploska A., Agid Y., Chase T.N. Continuous and intermittent levodopa differentially affect basal ganlia function. Ann. Neurol. 25:1989;473-478.
36. Lee C.S., Cenci M.A., Bjorklund A. Intrastriatal dopaminergic graft improves L-dopa induced dyskinesia in the rat model: implications for the mechanisms of L-dopa induced dyskinesia. Neurology. 48:1997;119. (Abstract).
37. Lees A.J., Stern G.M. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiat. 43:1981;143-150.
38. Leff S.E., Gariano R., Creese I. Dopamine receptor turnover rates in rat striatum are age-dependent. Proc. natn Acad. Sci. U.S.A. 81:1984;3910-3914.
39. 2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model. Brain Res. Bull. 28:1992;697-701.
40. Maneuf Y.P., Mitchell O.J., Crossman A.R., Woodruff G.N., Brotchie J.M. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res. 683:1995;102-108.
41. Marsden C.D., Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1:1977;345-349.
42. Matsumoto R.A., Brinsfield K.H., Ptrik R.L., Walker J.M. Rotational behavior mediated by dopaminergic and nondopaminergic mechanisms after intranigral microinjection of specific mu, delta, and kappa opioid agonists. J. Pharmac. exp. Ther. 246:1988;196-203.
43. Mattingly B.A., Rowlett J.K., Graff J.I., Hatton B.J. Effects of selective D1 and D2 dopamine antagonists on the development of behavioural sensitization to apomorphine. Psychopharmacology. 105:1991;501-507.
44. Mayfield R.D., Larson G., Zahniser N.R. Cocaine-induced behavioural sensitization and D1 dopamine receptor function in rat nucleus accumbens and striatum. Brain Res. 573:1992;331-335.
45. Mouradian M.M., Heuser I.J.E., Baronit F., Chase T.N. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann. Neurol. 27:1990;18-23.
46. Naranjo J.R., Mellström B., Achaval M., Sassone-Corsi P. Molecular pthways of pain: Fos/Jun-mediated activation of a noncanonical AP-1 site in the prodynorphin gene. Neuron. 6:1991;607-617.
47. Neve K.A., Neve R.L., Fields S., Janowsky A., Higgins G.A. Increased abundance of alternatively spliced forms of D2 dopamine mRNA after denervation. Proc. natn. Acad. Sci. U.S.A. 88:1991;2802-2806.
48. Newman D.D., Rajakumar N., Flumerfelt B.A., Stoessl A.J. A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. NeuroReport. 8:1997;669-672.
49. 2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys. Adv. Neurol. 60:1993;119-122.
50. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd :1986;Academic, NY.
51. Pearce R.K.B., Jackson M., Smith L., Jenner P., Marsden C.D. Chronic L-dopa administration induces dyskinesias in the MPTP-treated common marmoset (Cllithrix jacchus). Movement Disord. 10:1995;731-740.
52. Pilowsky P.M., Suzuki S., Minson J.B. Antisense oligonucleoties: a new tool in neuroscience. Clin. exp. Pharmacol. Physiol. 21:1994;935-944.
53. Pinna A., Morelli M., Drukarch B., Stoof J.C. Priming 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue. Eur. J. Pharmacol. 331:1997;23-26.
54. 2 dopamine receptor turnover and D2 messenger RNA levels in the neuroleptic-responsive and the neuroleptic nonresponsive lines of mice. J. Pharmacol. exp. Ther. 267:1993;1582-1590.
55. Robinson E.S.J., Nutt D.J., Jackson H.C., Hudson A.L. Antisense olionucleotides in psychopharmacology and behaviour: promises and pitfalls. J. Psychopharmacol. 11:1997;259-269.
56. Sonneberg J.L., Rauscher F.J.III, Morgan J.I., Curran T. Regulation of proenkephalin by Fos and Jun. Science. 246:1989;1622-1625.
57. Steiner H., Gerfen C.R. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behaviour. Exp. Brain Res. 123:1998;60-76.
58. Vezina P. D1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. J. Neurosci. 16:1996;2411-2420.
59. Wagner R.W. Gene inhibition using antisense oligodeoxynucleotides. Nature. 372:1994;333-335.
60. Wahlestedt C. Antisense olignucleotides strategies in neuropharmacology. Trends Pharmac. Sci. 15:1994;42-46.
61. Whitesell L., Geselowitz D., Chavany C., Fahmy B., Walbridge S., Alger J.R., Neckers L.M. Stability, clearance, and disposition of intraventriculary administered oligonucleotides: Implications for therapeutic application within the central nervous system. Proc. natn Acad. Sci. U.S.A. 90:1993;4665-4669.
62. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J. Pharmac. exp. Ther. 271:1994;1462-1470.